ZA200202276B - Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders. - Google Patents
Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders. Download PDFInfo
- Publication number
- ZA200202276B ZA200202276B ZA200202276A ZA200202276A ZA200202276B ZA 200202276 B ZA200202276 B ZA 200202276B ZA 200202276 A ZA200202276 A ZA 200202276A ZA 200202276 A ZA200202276 A ZA 200202276A ZA 200202276 B ZA200202276 B ZA 200202276B
- Authority
- ZA
- South Africa
- Prior art keywords
- hete
- group
- composition
- sodium salt
- alkyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 118
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims description 57
- 206010013774 Dry eye Diseases 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- YAZDSTCFFRZJLW-UHFFFAOYSA-N 2-hydroxyicosa-2,4,6,8-tetraenoic acid Chemical class CCCCCCCCCCCC=CC=CC=CC=C(O)C(O)=O YAZDSTCFFRZJLW-UHFFFAOYSA-N 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 87
- 150000003839 salts Chemical group 0.000 claims description 66
- 150000003904 phospholipids Chemical class 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- -1 15(S)-HETE sodium salt Chemical class 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000000607 artificial tear Substances 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 150000001768 cations Chemical class 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 238000009736 wetting Methods 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- 150000003077 polyols Chemical class 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229940099429 polyoxyl 40 stearate Drugs 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 claims description 4
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229940119743 dextran 70 Drugs 0.000 claims description 4
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 3
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 3
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 claims description 3
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 claims description 3
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims description 3
- 229940043234 carbomer-940 Drugs 0.000 claims description 3
- 229940031663 carbomer-974p Drugs 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 3
- 150000008106 phosphatidylserines Chemical class 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 67
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 38
- 239000002253 acid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 18
- JSFATNQSLKRBCI-VAEKSGALSA-N 15(S)-HETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 description 15
- 102000015728 Mucins Human genes 0.000 description 14
- 108010063954 Mucins Proteins 0.000 description 14
- 150000007513 acids Chemical class 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000008213 purified water Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940051875 mucins Drugs 0.000 description 6
- 102000003820 Lipoxygenases Human genes 0.000 description 5
- 108090000128 Lipoxygenases Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000001050 lubricating effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000003560 epithelium corneal Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000004489 tear production Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- IJAXPCZCTKDWBJ-VAGPFTOWSA-N (5e,8e,11e,13e)-icosa-5,8,11,13-tetraenoic acid Chemical compound CCCCCC\C=C\C=C\C\C=C\C\C=C\CCCC(O)=O IJAXPCZCTKDWBJ-VAGPFTOWSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 2
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 2
- BFWYTORDSFIVKP-USWFWKISSA-N 15-HPETE Chemical compound CCCCCC(OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-USWFWKISSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical group C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 2
- 229920001386 Gefarnate Polymers 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 108700020962 Peroxidase Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960003779 gefarnate Drugs 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 1
- ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 12(S)-HPETE Chemical compound CCCCC\C=C/C[C@H](OO)\C=C\C=C/C\C=C/CCCC(O)=O ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JSFATNQSLKRBCI-UDQWCNDOSA-N 15(R)-HETE Chemical compound CCCCC[C@@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-UDQWCNDOSA-N 0.000 description 1
- JSFATNQSLKRBCI-UHFFFAOYSA-N 15-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC(O)C=CC=CCC=CCC=CCCCC(O)=O JSFATNQSLKRBCI-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 1
- PQVHMOLNSYFXIJ-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazole-3-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(N1CC2=C(CC1)NN=N2)=O)C(=O)O PQVHMOLNSYFXIJ-UHFFFAOYSA-N 0.000 description 1
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 1
- JNUUNUQHXIOFDA-XTDASVJISA-N 5-HPETE Chemical compound CCCCC\C=C/C\C=C/C\C=C/C=C/C(OO)CCCC(O)=O JNUUNUQHXIOFDA-XTDASVJISA-N 0.000 description 1
- RDEYORKJEDLLDB-DQVHGTJVSA-N 5-Hydroperoxyeicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C(\OO)=C\C=C\C(O)=O RDEYORKJEDLLDB-DQVHGTJVSA-N 0.000 description 1
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000410536 Esme Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002669 Polyoxyl 20 Cetostearyl Ether Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940073464 benzododecinium bromide Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000001485 positron annihilation lifetime spectroscopy Methods 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-M tetracosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC([O-])=O QZZGJDVWLFXDLK-UHFFFAOYSA-M 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ZNEOHLHCKGUAEB-UHFFFAOYSA-N trimethylphenylammonium Chemical compound C[N+](C)(C)C1=CC=CC=C1 ZNEOHLHCKGUAEB-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Description
Hydroxyeicosatetraenoate Salts, Compositions and Methods of Use in Treating Dry Eye Disorders :
The present invention is directed to stable hydroxyeicosatetraenoate salt derivatives, compositions containing such salt derivatives and methods of preparation and use in treating dry eye.
Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying : severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eyelid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren’s disease and cicatricial pemphigoid manifest dry eye complications.
Although it appears that dry eye may result from a number of unrelated pathogenic causes, all presentations of the complication share a common effect, that is the breakdown of the pre-ocular tear film, which results in dehydration of the exposed outer surface and many of the symptoms outlined above (Lemp, Report of the
National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes, The CLAO
Journal, volume 21, number 4, pages 221-231 (1995)).
Practitioners have taken several approaches to the treatment of dry eye. One ) common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day. Other approaches include the use "of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
Examples of the tear substitution approach include the use of buffered, isotonic saline solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils. Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye,
Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley,
Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality, Archives of Ophthalmology, volume 116(7), pages 849-52 (1998). : 15 Examples of phospholipid compositions for the treatment of dry eye are disclosed in
United States Patent Nos. 4,131,651 (Shah et al.), 4,370,325 (Packman), 4,409,205 (Shively), 4,744,980 and 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.) and 5,578,586 (Glonek et al). U.S. Patent No. 5,174,988 (Mautone et al.) discloses phospholipid drug delivery systems involving phospholipids, propellants and an active substance.
United States Patent No. 3,991,759 (Urquhart) discloses the use of ocular inserts in the treatment of dry eye. Other semi-solid therapy has included the i -2-
aul administration of carrageenans (U. S. Patent No. 5,403,841, Lang) which gel upon contact with naturally occurring tear film. ;
Another approach involves the provision of lubricating substances in lieu of artificial tears. For example, United States Patent No. 4,818,537 (Guo) discloses the 5s use of a lubricating, liposome-based composition, and United States Patent No. 5,800,807 (Hu et al.) discloses compositions containing glycerin and propylene glycol for treating dry eye.
Aside from the above efforts, which are directed primarily to the alleviation of symptoms associated with dry eye, methods and compositions directed to treatment of the dry eye condition have also been pursued. For example, United States Patent No. 5,041,434 (Lubkin) discloses the use of sex steroids, such as conjugated estrogens, to treat dry eye conditions in post-menopausal women; United States Patent No. 5,290,572 (MacKeen) discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production; and United States Patent No. 4,966,773 (Gressel ct al.) discloses the use of microfine particles of one or more retinoids for . ocular tissue normalization.
Although these approaches have met with some success, problems in the treatment of dry eye nevertheless remain. The use of tear substitutes, while temporarily effective, generally requires repeated application over the course of a patient’s waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day. Such an undertaking is not only cumbersome and time consuming, but is also potentially very expensive.
Transient symptoms of dry eye associated with refractive surgery have been reported to last in some cases from six weeks to six months or more following surgery.
> WO 01/34549 PCT/US00/29227
The use of ocular inserts is also problematic. Aside from cost, they are often ) unwieldy and uncomfortable. Further, as foreign bodies introduced in the eye, they can be a source of contamination leading to infections. In situations where the insert does not itself produce and deliver a tear film, artificial tears must still be delivered on aregular and frequent basis.
In view of the foregoing, there is a clear need for an effective, convenient treatment for dry eye that is capable of alleviating symptoms, as well as treating the underlying physical and physiological deficiencies of dry eye.
Mucins are proteins which are heavily glycosylated with glucosamine-based moieties. Mucins provide protective and lubricating effects to epithelial cells, especially those of mucosal membranes. Mucins have been shown to be secreted by vesicles and discharged on the surface of the conjunctival epithelium of human eyes (Greiner et al.,, Mucous Secretory Vesicles in Conjunctival Epithelial Cells of Wearers of Contact Lenses, Archives of Ophthalmology, volume 98, pages 1843-1846 (1980); : 15 and Dilly et al, Surface Changes in the Anaesthetic Conjunctiva in Man, with Special
Reference to the Production of Mucous from a Non-Goblet-Cell Source, British
Journal of Ophthalmology, volume 65, pages 833-842 (1981)). A number of human- derived mucins which reside in the apical and subapical corneal epithelium have been discovered and cloned (Watanabe et al., Human Corneal and Conjunctival Epithelia
Produce a Mucin-Like Glycoprotein for the Apical Surface, Investigative
Ophthalmology and Visual Science, volume 36, number 2, pages 337-344 (1995)).
Recently, Watanabe discovered a new mucin which is secreted via the corneal apical and subapical cells as well as the conjunctival epithelium of the human eye (Watanabe et al, IOVS, volume 36, number 2, pages 337-344 (1995)). These mucins provide lubrication, and additionally attract and hold moisture and sebaceous material for lubrication and the corneal refraction of light. .
Mucins are also produced and secreted in other parts of the body including lung airway passages, and more specifically from goblet cells interspersed among tracheal/bronchial epithelial cells. Certain arachidonic acid metabolites have been shown to stimulate mucin production in these cells. Yanni reported the increased secretion of mucosal glycoproteins in rat lung by hydroxyeicosatetraenoic acid (“HETE”) derivatives (Yanni et al, Effect of Intravenously Administered Lipoxygenase
Metabolites on Rat Tracheal Mucous Gel Layer Thickness, International Archives of
Allergy And Applied Immunology, volume 90, pages 307-309 (1989)). Similarly,
Marom has reported the production of mucosal glycoproteins in human lung by HETE derivatives (Marom et al., Human Airway Monohydroxy- eicosatetraenocic Acid
Generation and Mucous Release, Journal of Clinical Investigation, volume 72, pages 122-127 (1983)).
Agents claimed for increasing ocular mucin and/or tear production include . vasoactive intestinal polypeptide (Dartt et. al., Vasoactive intestinal peptide- stimulated glycocongjugate secretion from conjunctival goblet cells. Experimental
Eye Research, volume 63, pages 27-34, (1996)), gefarnate (Nakmura et. al., Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from dessication in vivo, Experimental Eve Research, volume 65, pages 569-574 (1997)), liposomes (U.S. Patent No. 4,818,537), androgens (U.S. Patent No. 5,620,921), melanocycte stimulating hormones (U.S. Patent No. 4,868,154), phosphodiesterase inhibitors (U.S. Patent No. 4,753,945), and retinoids (U.S. Patent No. 5,455,265). However, many of these compounds or treatments suffer
N ’ WO 01/34549 PCT/US00/29227 from a lack of specificity, efficacy and potency and none of these agents have been : marketed so far as therapeutically useful products to treat dry eye and related ocular surface diseases.
U.S. Patent No. 5,696,166 (Yanni et al.) discloses compositions containing
HETEs and their derivatives and methods of use for treating dry eye. Yanni er al. discovered that compositions comprising HETEs increase ocular mucin secretion when administered to a patient and are thus useful in treating dry eye. Yanni et al. disclose a genus of HETESs including, without distinction, carboxylate salts. In fact, no examples of carboxylate salts are contained in the Yanni er al. patent. Instead, the only delineated compounds of the disclosed genus are the preferred compounds, 12(S)-HETE-free acid and 15(S)-HETE-free acid. The inventors of the present invention have found that the use of HETE free acids in the preparation of HETE compositions can result in the compositions exhibiting unsuitable shelf-life stability.
The inventors of the present invention have unexpectedly discovered that carboxylate . 15 salts of HETESs are particularly useful in the preparation of stable HETE compositions, and in methods of treating dry eye. Additionally, while HETE compositions are therapeutically useful in treating an underlying cause of dry eye, such compositions may not immediately alleviate the symptoms of dry eye following administration. In a preferred embodiment of the present invention, compositions providing both immediate and long term dry-eye relief are provided.
The present invention is directed to stable HETE salts. The present invention is also directed to methods of stabilizing HETE derivatives, compositions containing stabilized HETE derivatives, and the use of these compositions for the treatment of dry eye and other disorders requiring the wetting of the eye, including symptoms of dry eye associated with refractive surgery such as LASIK surgery.
More specifically, the present invention discloses methods of stabilizing
HETE denvatives by converting the compounds to their corresponding salts, lo preparing compositions containing salts of HETE derivatives, and methods of using the compositions for treating dry eye type disorders.
Preferred methods involve the preparation of compositions containing an effective amount of 15(S)-HETE-sodium salt and an effective concentration of ethanol. The compositions are preferably administered topically to the eye.
In a preferred embodiment, salts of HETE derivatives are formulated with an . artificial tear component or phospholipid in order to provide compositions that give both immediate and long term relief from dry eye or other disorders requiring the wetting of the eye.
FIG. 1 is a graph illustrating the improved stability of 15(S)-HETE-sodium salt . versus 15(S)-HETE free acid.
It has now been discovered that HETE salts are more stable than their corresponding acids, and the use of HETE salts in the preparation of pharmaceutical compositions improves the stability and shelf-life of such compositions. The HETE salt-containing compositions of the present invention are useful for the treatment of dry eye disorders. As used herein, the term “HETE salt” refers to any compound that stimulates ocular mucin production and/or secretion following topical ocular . application, and is of the following formulas (I), (II) or (II):
[8]
D; o
ZS Ta (II); and
[0]
J— Xn vO (II;
wherein:
M" is a pharmaceutically acceptable cation selected from the group consisting of: Na“,
K', Li*, Cs”, (A)N", wherein, A is independently H, alkyl, cycloalkyl, (cycloalkyl)alkyl, } alkyl(cycloalkyl), aryl, arylalkyl, heteroaryl, or (A),N" forms a heteroaryl, heterocycloalkenyl or heterocycloalkyl ring;
Yis —C— —Cc— . PALS i. or co 7 “on whereinR * * is H or OR! * is a functionally modified hydroxy group.
As used herein, the terms “pharmaceutically acceptable cation” means any cation (which together with the corresponding carboxylate forms a salt), that would be suitable for therapeutic administration to a patient by any conventional means without significant deleterious health consequences; and “ophthalmically acceptable cation” means any pharmaceutically acceptable cation (which together with the corresponding carboxylate forms a salt) that would be suitable for ophthalmic application, i.e. non- toxic and non-irritating.
The term “free hydroxy group” means an OH. The term “functionally modified hydroxy group” means an OH which has been functionalized to form: an ether, in which an alkyl, aryl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl, or heteroaryl group is substituted for the hydrogen; an ester, in which an acyl group is substituted for the hydrogen; a carbamate, in which an aminocarbony! group is substituted for the hydrogen; or a carbonate, in which an aryloxy-, heteroaryloxy-, alkoxy-, cycloalkoxy-, heterocycloalkoxy-, alkenyloxy-, cycloalkenyloxy-, heterocycloalkenyloxy-, or alkynyloxy-carbonyl group is substituted for the hydrogen. Preferred moieties include OH, OCH,C(O)CH3, OCH,C(O)C;Hs, : OCH;, OCH,CHj3, OC(O)CH3, and OC(O)C,Hs.
The term “acyl” represents a group that is linked by a carbon atom that has a double bond to an oxygen atom and a single bond to another carbon atom.
The term “alkyl” includes straight or branched chain aliphatic hydrocarbon groups that are saturated and have 1 to 15 carbon atoms. The alkyl groups may be substituted with other groups, such as halogen, hydroxyl or alkoxy. Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and s-butyl.
The term “cycloalkyl” includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more rings, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term “alkenyl” includes straight or branched chain hydrocarbon groups . 15 having 1 to 15 carbon atoms with at least one carbon-carbon double bond. The chain hydrogens may be substituted with other groups, such as halogen. Preferred straight or branched alkenyl groups include, allyl, 1-butenyl, 1-methyl-2-propenyl and 4- pentenyl.
The term “cycloalkenyl” includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more non- aromatic rings containing a carbon-carbon double bond, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkenyl groups include cyclopentenyl and cyclohexenyl.
The term “alkoxy” represents an alkyl group attached through an oxygen linkage. .
The term “carbonyl group” represents a carbon atom double bonded to an oxygen atom, wherein the carbon atom has two free valencies.
The term “alkoxycarbonyl” represents an alkoxy group bonded from its oxygen atom to the carbon of a carbonyl group, the carbonyl group itself being bonded to another atom through its carbon atom.
The term “aminocarbonyl” represents an amino group bonded from its nitrogen atom to the carbon atom of a carbonyl group, the carbonyl group itself being bonded to another atom through its carbon atom.
The term “lower alkyl” represents alkyl groups containing one to six carbons (C-Co)-
The term “halogen” represents fluoro, chloro, bromo, or iodo.
The term “aryl” refers to carbon-based rings which are aromatic. The rings may be isolated, such as phenyl, or fused, such as naphthyl. The ring hydrogens may . be substituted with other groups, such as lower alkyl, or halogen.
The term “heteroaryl” refers to aromatic hydrocarbon rings which contain at least one heteroatom such as O, S, or N in the ring. Heteroaryl rings may be isolated, with 5 to 6 ring atoms, or fused, with 8 to 10 atoms. The heteroaryl ring(s) hydrogens or heteroatoms with open valency may be substituted with other groups, such as lower alkyl or halogen. Examples of heteroaryl groups include imidazole, pyridine, indole, quinoline, furan, thiophene, pyrrole, tetrahydroquinoline, dihydrobenzofuran, and dihydrobenzindole.
. | WO 01/34549 PCT/US00/29227
The term “heterocycloalkyl]” refers to a cycloalkyl ring containing at least one ) heteroatom, such as N, O, or S, within the ring structure. Examples of heterocycloalkyl rings include tetrahydropyran, pyrrolidine, piperidine, piperazine, tetrahydrothiophene, and morpholine.
The term “heterocycloalkenyl” refers to a cycloalkenyl ring containing at least one heteroatom, such as N, O, or S, within the ring structure. Examples of heterocycloalkenyl rings include dihydropyran, pyrroline, and pyridone.
Included within the scope of the present invention are the individual enantiomers of the formula (I), (I) and (III) compounds, as well as their racemic and non-racemic mixtures. The individual enantiomers can be enantioselectively synthesized from the appropriate enantiomerically pure or enriched starting material by means such as those described below. Alternatively, they may be enantioselectively synthesized from racemic/non-racemic or achiral starting materials. (Asymmetric Synthesis; J. D. Morrison and J. W. Scott, Eds.; Academic Press : 15 Publishers: New York, 1983-1985, volumes 1-5; Principles of Asymmetric Synthesis;
R.E. Gawley and J. Aube, Eds.; Elsevier Publishers: Amsterdam, 1996). They may also be isolated from racemic and non-racemic mixtures by a number of known methods, e.g. by purification of a sample by chiral HPLC (A Practical Guide to Chiral
Separations by HPLC; G. Subramanian, Ed.; VCH Publishers: New York, 1994;
Chiral Separations by HPLC; AM. Krstulovic, Ed.; Ellis Horwood Ltd. Publishers, 1989), or by enantioselective hydrolysis of a carboxylic acid ester sample by an enzyme (Ohno, M.; Otsuka, M. Organic Reactions, volume 37, page 1 (1989)). Those skilled in the art will appreciate that racemic and non-racemic mixtures may be obtained by several means, including without limitation, nonenantioselective synthesis, partial resolution, or even mixing samples having different enantiomeric ratios. Departures may be made from such details within the scope of the accompanying claims without departing from the principles of the invention and without sacrificing its advantages. Also included within the scope of the present invention are the individual isomers substantially free of their respective enantiomers.
Preferred HETE salts of the present invention are those wherein M” is selected from the group consisting of Na’, K', NH,", benzyltrimethylammonium ion, tetrabutylammonium ion, and phenyltrimethyl ammonium ion. The most preferred compounds of the present invention are: — — COO-Na+
CTC
H “oH 5,8,11,13-Eicosatetraenoic acid, 15-hydroxy- [158-(5Z,8Z,11Z,13E)]- sodium salt - ‘ (“15(S)-HETE - sodium salt”); and — = COO-Na+ :
HO “H 5,8,11,13-Eicosatetraenoic acid, 15-hydroxy- [15R-(5Z,8Z,11Z,13E)]- sodium salt - (“15(R)-HETE - sodium salt”).
The HETE salts of the present invention are prepared from the respective
HETE free acids (i.e., from compounds of formulas I, II and III, wherein M" is H).
The HETE free acids are typically derived from arachidonic acid. Certain of the HETE free acids are known in the art and have been isolated ex vivo as well as prepared biosynthetically and synthetically. HETE free acids are made endogenously by the action of lipoxygenases or other enzymes and subsequent reductions through the actions of endogenous peroxidases. Several lipoxygenases are known to exist and ’ are named for the carbon position which they oxidize. Such enzymes include 5- lipoxygenase, 12-lipoxygenase and 15-lipoxygenase. Other enzymes such as cytochrome P-450 have been observed to catalyze the formation of “R-type” HETE oxidized products. Each lipoxygenase catalyzes the addition of a hydroperoxy group at the respective carbon. After hydroperoxidation, which forms such molecules as 5- hydroperoxyeicosatetraenoic acid (“5-HPETE”), 12-HPETE and 15-HPETE, the arachidonate derivatives are reduced to the resulting alcohol by various peroxidases.
The resulting molecules include 5-HETE, 12-HETE and 15-HETE free acid.
HETE free acids can be obtained bio-synthetically, by in vitro synthesis. Such methods have involved the use of the respective lipoxygenase, O,, arachidonic acid and a suitable reducing agent (See, Martini et al.,, Regiocontrol of Soybean
Lipoxygenase Oxygenation. Application to the Chemoenzymatic Synthesis of Methyl 15(S)-HETE and Dimethyl 5(S)-, 15(S)-HETE. Joumal of Organic Chemistry, volume : 15 61, pages 9062-9064 (1996); Graff et al., Activation of Soluble Splenic Cell Guanylate
Cyclase by Prostaglandin Endoperoxides and Fatty Acid Hydroperoxides, Journal of
Biological Chemistry, volume 253, pages 7662-7676 (1978) and Graff, Preparation of 15-L-Hydroperoxy-5,8,11,13- eicosatetraenoic acid (15-HPETE), Methods in
Enzymology, volume 86, pages 386-392 (1982)). HETE free acids may also be synthesized by organic synthetic routes such as described in Corey et al., J2-Hydroxy- 5,8, 14-(2)-10-(E)-eicosatetraenoic Acid (12-HETE), The logic of Chemical
Synthesis, John Wiley and Sons, sections 12.9 and 12.11 (1989). Finally, HETE free acids are commercially available from various sources including Sigma Chemical Co. (St. Louis, Missouri) and Cayman Chemical (Ann Arbor, Michigan). The level of peroxy compounds in the HETE salt raw materials that are used to prepare the pharmaceutical formulations of the present invention may have an impact on the
HETE salt’s biological activity. Although the precise relationship has not been defined, it is preferable to use HETE salt raw material supplies containing peroxy compounds at levels no greater than about 0.3 ppm. Methods for determining peroxy levels are known in the art (e.g., European Pharmacopoeia 1997 3" Ed., Method 2.5.5 — Peroxide Value).
The HETE salts of the present invention are prepared using the following
Scheme 1:
Scheme 1
HETE free acid XM HETE salt
In the above Scheme 1, X-M, which is a base comprised of a positive ion M", as described above, is added to either the neat HETE free acid, or as dissolved in a solvent, e.g., ethanol. The molar ratio of X-M to HETE free acid will typically range from about 1:1 to 2:1, but is preferably, 1:1. The resultant HETE salt is typically filtered under vacuum and concentrated by rotary evaporation several times and finally dried under high vacuum to yield the neat HETE salt.
v ) WO 01/34549 PCT/US00/29227
Example 1
Preparation of 15¢(5)-HETE-sodium salt.
To a solution of 8.71g (27.2 mmol) of 15(S)-HETE acid in 500 mL of absolute 5s ethanol under nitrogen at room temperature was added a solution of 2.28 g (27.2 mmol) of sodium bicarbonate in 60 mL of deionized water. The resulting cloudy mixture was stirred for 1.5 hours until gas evolution had ceased and only faint cloudiness remained, then filtered under vacuum and concentrated by rotary evaporation under vacuum (bath, 24° C). Absolute ethanol was added to dissolve the residue, and the solution was concentrated as in the previous step. The redissolution/filtration/concentration step was performed twice more. The residue was then dried under vacuum for 16 hours, affording 9.23 g (99%) of the sodium salt of 15(S)-HETE as white powdery solid.
C-NMR (CD;OD): & 14.39 (CH), 23.68, 26.27, 26.56, 26.97, 27.33, 28.12, 32.97, } 15 37.67,38.42 (CH,), 73.30, 126.22, 128.61, 129.22, 129.38, 129.71, 130.59, 130.78, 137.98 (CH), 181.36 (CO;Na).
Example 2
Preparation of 15(S)-HETE-ammonium salt.
Ammonium hydroxide (0.5 mL of a 15 molar aqueous solution) was added to a solution of 0.35 g of 15(S)-HETE in 10 mL of absolute ethanol. The resulting solution was concentrated by rotary evaporation under vacuum. Absolute ethanol (10 mL) was added to the residue and the resulting solution was concentrated by rotary evaporation under vacuum to yield 0.33 g of the ammonium salt of 15(S)-HETE as an oil. )
The present invention is also directed to stable, stock compositions comprising . one or more HETE salts and ethanol. The inventors have found that storing the HETE salts in an ethanolic solution provides greater stability of the HETE salts over analogous aqueous compositions, or neat HETE salt compositions. Such compositions comprise one or more HETE salts and an amount of ethanol to solubilize the HETE salt in solution. The HETE salt, now dissolved in the ethanolic vehicle is in ionized form. Such resultant compositions are also contemplated by the present invention. Preferably, the ethanolic stock solutions will contain anhydrous ethanol, but aqueous ethanolic solutions are also contemplated hereunder. Generally, the stock solutions will contain ethanol in a concentration of about 25 to 100 % volume/volume (“v/v”). Typically, such stock solutions will contain HETE salts in a : higher concentration relative to the pharmaceutical compositions of the present invention.
The pharmaceutical compositions of the present invention comprise one or more HETE salts in an amount effective to secrete mucin in the eye and thus eliminate or improve dry eye conditions when administered to the eye. As used herein, the term “pharmaceutically effective amount” refers to an amount of one or more HETE salts which improves the dry eye condition in 2 mammal. Generally, the HETE salts will be contained in the pharmaceutical compositions in concentrations ranging from about 0.00001 to about I per cent weight/volume (“% w/v"), and preferably, about 0.00001 to 0.01% w/v. Compositions comprising 15(S)-HETE salt in a concentration of from about 0.00001 to 0.0001% w/v are most preferred.
v i WO 01/34549 PCT/US00/29227
The HETE salt pharmaceutical compositions will be formulated as solutions, : suspensions and other dosage forms for topical administration. Aqueous solutions are generally preferred, based on ease of formulation, biological compatibility (especially in view of the malady to be treated, i.e., dry eye-type disorders), as well as a patient’s ability to easily administer such compositions by means of instilling one to two drops of the solutions in the affected eyes. However, the HETE salt pharmaceutical compositions may also be suspensions, viscous or semi-viscous gels, or other types of solid or semi-solid compositions. Suspensions may be preferred for HETE salts which are less soluble in water.
Preferably, the pharmaceutical compositions of the present invention will also contain ethanol. As used herein, “an effective concentration of ethanol” refers to a concentration that enhances the biological efficacy of the HETE salt compositions when dosed topically to the eye. In general, the concentration of ethanol necessary for : the enhancement of the HETE salts is believed to be somewhat proportional to the : 15 concentration of the HETE salt(s) administered. If a relatively high concentration of
HETE salt, e.g., above 0.01% w/v, is administered, the concentration of ethanol in such compositions may be proportionally less than analogous compositions containing lower concentrations of HETE salts. In general, however, the ethanol concentration contained in the compositions of the present invention will range from about 0.001- 2% w/v. Compositions containing HETE salt concentrations of about 0.00001-0.01% w/v preferably will contain ethanol in a concentration of about 0.005-0.20% w/v, and most preferably, about 0.02-0.10% w/v.
Preferably, the pharmaceutical compositions of the present invention will also contain one or more surfactant(s). The surfactant(s) may provide additional chemical stabilization of the HETE salts and may further provide for the physical stability of the
HETE salts. In other words, the surfactants may aid in preventing chemical : degradation of the HETE salts and also prevent the salts from binding to the containers in which their compositions are packaged. Various surfactants useful in s topical ophthalmic formulations may be employed. Examples of surfactants include, but are not limited to: Cremophor® EL, polyoxyl 20 ceto stearyl ether, polyoxyl 40 hydrogenated castor oil, polyoxyl 23 lauryl ether and poloxamers, e.g., poloxamer 407. A preferred surfactant is polyoxyl 40 stearate. The amount of surfactant will vary, depending on the amount of HETE salt(s) and the presence of any ethanol included in the formulation. In general, however, the surfactant(s) concentration will be about 0.001 to 2.0% w/v. Preferred pharmaceutical compositions of the present invention will contain about 0.1% w/v of polyoxyl 40 stearate.
The pharmaceutical compositions of the present invention may also include various other ingredients, such as tonicity agents, buffers, preservatives, co-solvents and antioxidants. .
Various tonicity agents may be employed to adjust the tonicity of the pharmaceutical composition, preferably to that of natural tears. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride and/or mannitol may be added to the composition to approximate physiological tonicity. Such an amount of tonicity agent will vary, depending on the particular agent to be added. In general, however, the compositions will have a tonicity agent concentration of about 0.1-1.5% w/v. Preferred pharmaceutical compositions will contain about 0.75% w/v of sodium chloride.
v WO 01/34549 PCT/US00/29227
An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium ) citrate, sodium borate or boric acid) may be added to prevent pH drift under storage conditions. The particular concentration will vary, depending on the agent employed.
In general, such a concentration will range from about 0.02 to 2.0% w/v. Preferred compositions will contain about 0.25% w/v of boric acid.
Topical ophthalmic products are typically packaged in multidose form.
Preservatives are thus required to prevent microbial contamination during use.
Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but : typically unpreserved. Such compositions, therefore, generally will not contain preservatives. : 15 Antioxidants may be added to compositions of the present invention to protect the HETE salts from oxidation during storage. Examples of such antioxidants include, but are not limited to, vitamin E and analogs thereof, ascorbic acid and derivatives, and butylated hydroxyanisole (BHA).
In a preferred embodiment, the pharmaceutical compositions of the present invention include one or more artificial tear or phospholipid components to provide immediate relief while the HETE salts stimulate natural tear production. In this embodiment, the compositions of the present invention provide a two-pronged approach to the treatment of dry eye. The artificial tear or phospholipid component of the compositions provides immediate, temporary relief of dry eye by lubricating and wetting the eye, and the HETE derivative component of the compositions provides pharmaceutical therapy by stimulating the rebuilding of the patient’s natural tears through the stimulation of ocular secretion of mucin. An advantage of compositions according to this embodiment, which provide both immediate, temporary relief as well as long-term dry eye relief, is that they do not need to be administered at high frequency typical of non-therapeutic phospholipid compositions. Instead, the compositions of the present invention may be administered as little as one to two times per day to as much as only about eight to ten times a day, depending on the severity of the dry eye condition.
Another advantage of the compositions containing a HETE salt and an artificial tear or phospholipid component is that the compositions provide ease of use over separate, single therapy compositions. In order for a patient to even attempt to gain both short-term and long-term dry eye relief, the patient would need to juggle two separate composition dosing regimens. With such a two composition regimen, the 1s user is encumbered with handling two separate compositions and following the . different dosing regimens. Additionally, due to possible overlap of administration, a user of two separate systems may inadvertently overdose one composition or the other, or effectively over-dilute one composition or the other by concomitant dosing of the two compositions. The present invention would solve such problems by providing a single, multi-therapeutic composition for the treatment of dry eye-type diseases and disorders.
As used herein, “one or more artificial tear or phospholipid components” refers to those components that: (i) lubricate, “wet,” approximate the consistency of endogenous tears, or otherwise provide temporary relief of the dry eye symptoms and v WO 01/34549 PCT/US00/29227 conditions upon ocular administration; (ii) are safe; and (iii) provide an appropriate delivery vehicle for the topical administration of an effective amount of one or more
HETE derivatives. As used herein, “an effective amount of one or more artificial tear or phospholipid components” refers to that amount which lubricates, “wets,” approximates the consistency of endogenous tears, or otherwise provides temporary relief of the dry eye symptoms and conditions upon ocular administration. In general, the concentration of the artificial tear or phospholipid components in the compositions of the present invention will range from about 0.01 to about 1.0% w/v (phospholipid component) or 2.0% w/v (non-phospholipid component). Preferred amounts will range from about 0.05 to about 0.1% w/v (phospholipid components) and 0.1 — 0.5% wiv (non-phospholipid component). - The phospholipid components useful in the compositions of the present invention are any natural or synthetic phospholipid compounds comprising a glycerol- : phosphoric acid ester or sphingosine backbone. Examples of phospholipids of the . 15 present invention are of formula (IV): 21__
R2 EAN c _-X R4
H—C—X#2—R,
I
M~0—p—r,
OH av) wherein, X*' and X** are the same or different and are O, NH(C=0), O(C=0), or a direct bond;
R* is H or CH=CH(CH,),,CH3;
X22. R'is OH, or R'is C226 substituted or unsubstituted alkyl or alkenyl;
R? is C2.26 substituted or unsubstituted alkyl or alkenyl; and
R’ is OH, OCH,CH(NH;")COO’, OCH;CH,NH;", OCH,CH,N'(CH;)s,
OCH,CH(OH)CH,OH and O-inositol.
The phospholipids may be present as racemic or non-racemic compounds.
Preferred phospholipids are those wherein X?'-R' and/or X*2-R? comprise fatty acid esters or amides. Natural fatty acids are saturated, monounsaturated or polyunsaturated. Examples of fatty acid residues include, but are not limited to, laurate, myristate, palmitate, palmitoleate, stearate, oleate, linoleate, linolenate, eicosanoate, docosanoate and lignocerate. Preferred phospholipid types are the phosphatidylethanolamines, phosphatidylcholines, phosphatidylserines, phospatidylinositols and sphingomyelins. Examples of specific phospholipids include: 1,2-dipalmitoyl phosphatidyl choline (“DPPC”) 1,2-dipalmityl phosphatidyl glycerol (“DPPG”), N-stearyl sphingomyelin, N-palmityl sphingomyelin, N-oleyl sphingomyelin, 1,2-distearoyl phosphatidyl ethanolamine (“DSPE”), 1,2-distearoyl phosphatidyl inositol (“DSPI”), 1-stearoyl-2-palmitoyl phosphatidyl ethanolamine (“SPPE”), 1-stearoyl-2-palmitoyl phosphatidyl choline (“SPPC”), 1,2-dipalmitoyl phosphatidyl ethanolamine (“DPPE”), 1,2-dioleoyl phophatidyl ethanolamine (“DOPE”), 1,2-dioleoy! phophatidyl serine (“DOPS”), and 1,2-dipalmitoyl phosphatidyl serine (“DPPS™). The most preferred phospholipid carriers are the phosphatidylethanolamines and sphingomyelins. Phospholipids are available from a variety of natural sources and may be synthesized by methods known in the art; see, for example, Tsai et. al., Biochemistry, volume 27, page 4619 (1988); and Dennis et. al., Biochemistry, volume 32, page 10185 (1993).
Various non-phospholipid artificial tear components are known and are useful in providing lubrication, “wetting,” approximation of the consistency of endogenous
‘ | WO 01/34549 PCT/US00/29227 tears, or otherwise providing temporary relief of the dry eye symptoms and conditions : upon ocular administration. Such compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose (“HPMC”), carboxy methylcellulose sodium, and hydroxy propylcellulose (“HPC”); hyaluronic acid; chondroitin sulfate; dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941, carbomer 940, carbomer 974P. In general, the compositions will exhibit a viscosity of 1 to 400 centipoises (“cps”). Preferred compositions will exhibit a viscosity of about 25 cps.
The pharmaceutical compositions of the present invention are intended for administration to a mammal suffering from dry eye or symptoms of dry eye. As such, the compositions of the present invention will be administered topically. In general, . 15 the doses used for the above described purposes will vary, but will be in an effective amount to alleviate the symptoms of dry eye, increase mucin production in the eye and thus eliminate or improve dry eye conditions. As used herein, the term “therapeutically effective amount” refers to an amount of compositions of the present invention administered to a patient which improves the dry eye condition of the patient. Generally, 1-2 drops of the pharmaceutical compositions of the present invention will be administered 1-10 times per day for the treatment of dry eye or other ocular disease or disorder. Preferably, 1-2 drops of the compositions will be administered 1-4 times per day.
As used herein, the term “pharmaceutically acceptable carrier” refers to any formulation that is safe, and provides the appropriate delivery for the desired route of . administration of an effective amount of at least one HETE salt of the present invention.
The following examples describe compositions of the present invention.
Variations of the exemplified compositions may also be prepared, e.g., substituting another HETE salt for 15(S)-HETE-sodium salt and/or modifying the concentration of the HETE salt to between about 0.00001 to 1% w/v, varying the concentrations of the other components present, and modifying the pH (e.g., between about 6-8).
Example 3 15(5)-HETE-sodium salt 0.000034
EZ ET oon | om
Sodio Chloride os
Diss | oo
Polyguaternium-1 0.001
NaORHCI
Purified Water as. 100%
The above composition is prepared by the following method: The batch quantities of polyoxyl 40 stearate, boric acid, sodium chloride, disodium edetate, and polyquaternium-1 are weighed and dissolved by stirring in 90% of the batch quantity of i5 purified water. The pH is adjusted to 7.5 £ 0.1 with NaOH and/or HCl. Under yellow
Light or reduced lighting, the batch quantity of 15(S)-HETE sodium salt as a stock v WO 01/34549 PCT/US00/29227 solution in ethanol and the additional quantity of ethanol necessary for the batch are ) measured and added. Purified water is added to bring the solution to 100% (“q.s.”).
The mixture is stirred for five minutes to homogenize and then filtered through a sterilizing filter membrane into a sterile recipient.
Preferably, the above process is performed using glass, plastic or other non- metallic containers or containers lined with such materials.
The formulations of Examples 4 and 5 may be made by a method similar to that described in Example 3.
Example 4
I
15(S)-HETE-sodium salt 0.000034
Boca | 0s oo Disodium Edetae | oor
Polyquaternium-1 0.001
NaOH/HCI gs. pH="7.5
Purified Water q-s- 100%
Example S . 15(5)-HETE-sodium salt 0.000034 ons | om
NaOH/HCI q.s.,pH=17.5
The following Examples 6-7 illustrate the stability of a HETE salt versus the corresponding HETE free acid.
Example 6 15(S)-HETE free acid and 15(S)-HETE-sodium salt were stored under ambient air for four days and exposed to either a temperature of 40° C in total darkness, or ambient temperature and 300 foot-candles of light (approximately Standard Fluorescent
Room Light). Following the four day exposure, aliquots of the samples were analyzed by HPLC for percent remaining HETE and results are reported in Table 1:
Table 1
Sample Condition % of Initial
Amount -
Remaining 15(S)-HETE-free acid (oil) Ambient temp., 300 F-C light 15(S)-HETE-free acid (oil) 40° C, dark 0 15(S)-HETE-sodium salt (solid) | Ambient temp., 300 F-C light 15(S)-HETE-sodium salt (solid) | 40° C, dark 86
The above data illustrate that the storage of HETEs as free acids results in a ’ high degree of degradation at relatively mild conditions versus the relatively stable storage of the corresponding salts. Thus, this example illustrates the utility of stabilizing HETESs as salts and preparing HETE compositions using HETE salts.
Example 7
Ethanolic stock solutions of 15(S)-HETE free acid and 15(S)-HETE free acid with an approximately equimolar amount of sodium hydroxide (to form the sodium salt in situ) were aliquoted to amber glass vials and dried under a stream of helium.
The vials were stored at room temperature under ambient atmosphere. At various times, two vials of each were reconstituted with an aliquot of 50/50 acetonitrile/water and assayed by HPLC for 15(S)-HETE. The results are shown in Table 2 and : illustrated in Figure 1:
Table 2 (Hours) Sodium Salt Acid % Remaining % Remaining
IEC LU
I EC
I EC
0s [°°
As illustrated above, the sodium salt of 15(S)-HETE is more stable than the corresponding free acid.
The following example illustrates the stabilizing effects of ethanol on the
HETE salts of the present invention.
Example 8 15(S)-HETE-sodium salt as the neat solid under argon or as solutions in absolute ethanol under ambient atmosphere were stored in amber glass vials in a - 20°C freezer or at room temperature. At various times, the samples were analyzed by
HPLC for percent of initial 15(S)-HETE remaining. The results are reported in Table 3:
Table 3 ew mem ale a ample 0,
ET Ee EE EE
Err I EC EC BC EC 5 -
EE wv [0 [0 ¢ Stored under argon in amber glass vials. ® Stored under ambient atmosphere in amber glass vials.
The above data demonstrate that the compositions comprising HETE sodium salts in ethanol were more stable through a variety of conditions than the corresponding neat solids. Thus, this example illustrates the utility of stabilizing
HETE salts as solutions in ethanol and preparing HETE salt pharmaceutical compositions using HETE salt stock solutions in ethanol.
+ WO 01/34549 PCT/US00/29227
The following Examples 9-14 (phospholipid compositions) and 15-23 (non- phospholipid artificial tear component compositions) illustrate specific compositions } of the present invention.
Example 9 [wee] momoe 15(5)-HETE Sodium Salt 0.000034
Sim ios IC . Dibasic Sodium Phosphate 0.025
NaOH/HCI qs to pH 6-8
The above composition is prepared by the following method. The batch quantities of DPPC, DPPG, sodium chloride, potassium chloride, dibasic sodium phosphate, disodium EDTA, polyquaternium-1, are weighed and dissolved by stirring in 90% of the batch quantity of purified water. The pH is adjusted to 7.5 + 0.1 with NaOH and/or HCl. Under yellow light or reduced lighting, the batch quantity of 15(S)-HETE sodium salt as a stock solution in ethanol and the additional quantity of ethanol necessary for the batch are measured and added. Purified water is added to q.s. to 100%.
The mixture is stirred for five minutes to homogenize and then filtered through a sterilizing filter membrane into a sterile recipient. :
Preferably, the above process is performed using glass, plastic or other non- . metallic containers or containers lined with such materials.
The formulations of Examples 10 — 14 may be made by a method similar to that described in Example 9.
Example 10 15(S)-HETE Sodium Salt 0.000034
Dibasic Sodium Phosphate 0.025
Polyquaternium-1 0.001 + 10% excess ’ pos ECE
NaoH/HCI gs to pH 6-8
+ WO 01/34549 PCT/US00/29227 ’ Example 11
ET TT
Eames] omen ewan
CA ER
EE RTE
[somos [on
Er I [omic somommrogme | oms [Dwi | on [robpmenment | 0001 omens rseavaer | 0
ER TTR
Example 12
TR
[Nomi sommgoman | om oe [ow
Sommaire os [romano on [Dic soivmprope | tos
Er Kr
Psa | @ i : | J
Example 13 mm Gv
HETE derivative 0.00001-0.01 : ; ) ! Dibasic Sodium Phosphate 0.025
Polyquaternium-1 0.001 + 10% excess : NaOH/HCI gs to pH 6-8
Example 14 [ein momo
HETE derivative 0.00001-0.01
Dibasic Sodium Phosphate 0.025
Polyquaternium-1 0.001 + 10% excess
NaoH/HCI gs to pH 6-8
+ WO 01/34549 PCT/US00/29227 ) Example 15
Esme | omos [romotiseme | or
EE BTR ovmmiors | on
The above composition is prepared by the following method. The batch quantities of HPMC, dextran 70, benzalkonium chloride, sodium chloride, potassium chloride and disodium EDTA are weighed and dissolved by stirring in 90% of the batch quantity of purified water. The pH is adjusted to 7.5 + 0.1 with NaOH and/or HCL 5s Under yellow light or reduced lighting, the batch quantity of 15(S)-HETE sodium salt as a stock solution in ethanol and the additional quantity of ethanol necessary for the batch are measured and added. Purified water is added to q.s. to 100%. The mixture is stirred for five minutes to homogenize and then filtered through a sterilizing filter membrane into a sterile recipient.
Preferably, the above process is performed using glass, plastic or other non- metallic containers or containers lined with such materials.
The formulations of Examples 16 — 23 may be made by a method similar to that described in Example 15. :
Example 16 wey
ER TTR ew
EY I
EE ET omit on]
ET
CE
Example 17
EE ams] oor
Eo | ows ew [ohms | om wives | @
ET NTT
1
Example 18
Semcon | ow
Magnesium Chloride 0.0065
Treas wows
Con DiiasnaOE | wiopon
Er
Example 19 osm] ooms veo [smoionse [aw rossi cones | on]
Example 20 15(S)-HETE Sodium Salt 0.000034
Polyoxyl 40 Stearate
Carbomer 934
Purified Water oe
NaOH/HC! gs to pH 6-8
Example 21 ear 15(S)-HETE Sodium Sait 0.000034
EE
Benzalkonium Chloride 0.008 + 5% excess
NaOH/HCI gs to pH 6-8
Example 22 moi 15(S)-HETE Sodium Salt 0.000034
EE TR
Carbomer 934P 0.175
CE TR
Fut vi
NaOH/HCI gs to pH 6-8
A] N .
A] 15(S)-HETE Sodium Salt 0.000034
Polyocy] 40 Sear -
ET NC
Calcium Chloride 0.0053
Magnesium Chlonde 0.0065
Carbon Dioxide/NaOH/HCI gs to pH 6-8 =r oe
The invention in its broader aspects is not limited to the specific details shown and described above. - Departures may be made from such details within the scope of the 5s accompanying claims without departing from the principles of the invention and without sacrificing its advantages.
The unit “cps” which is used in the specification and which is not in accordance with the metric system may be converted with the aid of the following conversion factor: Co : To convert from To Multiply by
J [— - centipoise (cps) pascal second (Pa.s) ~~ 1x10? ) : 39 - i
AMENDED SHEET 2002-10-02
Claims (30)
1. In a pharmaceutical composition for treating dry eye and other disorders requiring the wetting of the eye comprising a HETE derivative according to formulas (1), (I) or (I): s — — (a; — C(O)X = NNT Y (II); and p— — C(O)X CT Y am); - 10 wherein: X is OR or NHR’; - R is H, a cationic pharmaceutically acceptable salt moiety, substituted or unsubstituted alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, arylalkyl, wherein the substitution is made with a moiety selected from the group consisting of: alkyl, halogen, hydroxy and functionally modified hydroxy; R" is H, substituted or unsubstituted alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, arylalkyl, wherein the substitution is made with a moiety selected from the group consisting of: alkyl, halogen, hydroxy and functionally modified hydroxy; and Y is — Cc or AT Wor ro? “W. wherein R' * is H or C(O)R’,
the improvement wherein the HETE derivative is an improved stability HETE derivative having X = the pharmaceutically acceptable salt moiety OM"; M" is a pharmaceutically acceptable cation selected from the group consisting of: Na", K', Li’, Cs, (A)sN"; and A is independently H, alkyl, cycloalkyl, (cycloalkyl)alkyl, alkyl(cycloalkyl), aryl, arylalkyl, heteroaryl, or (AMN' together form a heteroaryl, heterocycloalkenyl or heterocycloalkyl ring;
2. The pharmaceutical composition of Claim 1 wherein the HETE derivative is selected from the group consisting of: 5(S)-HETE-sodium salt, 5(R)-HETE-sodium salt, 12(S)-HETE-sodium salt, 12(R)-HETE-sodium salt, 15(S)-HETE-sodium salt, 15(R)-HETE-sodium salt and racemic and non-racemic mixtures thereof.
3. The pharmaceutical composition of Claim 2 wherein the HETE derivative is 15(S)-HETE-sodium salt.
4, The pharmaceutical composition of Claim 1 wherein M" is selected from the group consisting of Na', K™ and NH,"
5. An improved stability HETE derivative composition comprising ethanol and one or more HETE derivatives according to formulas (I), (II) or (IIT): 0]
oO (om = Y Nee TNS (11); and 0} — AS vy ONT (Im); wherein, M" is a pharmaceutically acceptable cation selected from the group consisting of: Na*, 5s K',LiY, Cs', (R)N", wherein, R is independently H, alkyl, cycloalkyl, (cycloalkyl)alkyl, alkyl(cycloalkyl), aryl, arylalkyl, heteroaryl, or (R);N' together form a heteroaryl, heterocycloalkenyl or heterocycloalkyl ring; Yis Cr or —c uw’ ” or" ro” “Hu . . wherein R' ' is Hor OR! is a functionally modified hydroxy group.
6. The pharmaceutical composition of Claim 5 wherein the composition comprises 0.001 — 2% (w/v) ethanol.
7. The composition of Claim 5 further comprising one or more artificial tear or phospholipid components.
8. The composition of Claim 7 wherein the composition comprises a phospholipid selected from the group consisting of are selected from the group consisting of phosphatidylethanolamines, phosphatidylcholines, phosphatidylserines, phospatidylinositols and sphingomyelins.
9. The composition of Claim 7 wherein the composition comprises a phospholipid of the formula: 21__ Ay X"—R, H—C—X%2—R, I H,C 2 TORR, OH av) wherein, X*! and X** are the same or different and are O, NH(C=0), O(C=0), or a direct bond; R* is H or CH=CH(CH,),,CH3;
X*'.R'is OH, or R! is C,,.5¢ substituted or unsubstituted alkyl or alkenyl; R? is C)2.26 substituted or unsubstituted alkyl or alkenyl; and R® is OH, OCH,CH(NH;")COO, OCH,CH,NH;", OCH,CH,N" (CHa), OCH,CH(OH)CH,0H and O-inositol.
10. The composition of Claim 9, wherein the phospholipid is selected from the group consisting of: DPPC, DPPG, DSPI, SPPC, DPPE, DOPS, DSPE, SPPE, DOPE, DPPS, N-stearyl sphingomyelin, N-palmityl sphingomyelin and N-oleyl sphingomyelin.
11. The composition of Claim 7 wherein the composition comprises an artificial tear component selected from the group consisting of monomeric polyols; polymeric polyols; hyaluronic acid; chondroitin sulfate; dextrans; water-soluble proteins; and vinyl polymers.
12. The composition of Claim 11 wherein the artificial tear component is selected from the group consisting of glycerol; propylene glycol; ethylene glycol; polyethylene glycol; hydroxypropylmethyl cellulose; carboxy methylcellulose sodium; hydroxy propylcellulose; hyaluronic acid; chondroitin sulfate; dextran 70; gelatin; polyvinyl alcohol; polyvinylpyrrolidone; povidone; carbomer 934P; carbomer 941; carbomer 940; and carbomer 974P.
13. The composition of Claim 5, wherein the composition further comprises one s or more ingredients selected from the group consisting of surfactants, tonicity agents, buffers, preservatives, co-solvents and anti-oxidants.
14. A method for the treatment of dry eye and other disorders requiring the wetting of the eye comprising administering to a mammal a composition comprising cthanol, a pharmaceutically acceptable carrier and a pharmaceutically effective amount of one or more HETE salts according to formulas (I), (II) or (III): (o] @; _ o Z ETN (II); and (o} — NN (I); wherein, M" is a pharmaceutically acceptable cation selected from the group consisting of: Na*, K', Li", Cs", (R)aN",
wherein, R is independently H, alkyl, cycloalkyl, (cycloalkylalkyl, alkyl(cycloalkyl), aryl, arylalkyl, heteroaryl, or (R);N* together form a heteroaryl, heterocycloalkenyl or heterocycloalkyl ring; Yis . — Cc or Cc S Ww “or ra? “H, wherein R' ' is Hor OR"! is a functionally modified hydroxy group.
15. The method of Claim 14, wherein the HETE salt is selected from the group consisting of 5(5)-HETE-sodium salt, 5(R)-HETE-sodium salt, 12(S)-HETE-sodium salt, 12(R)-HETE-sodium salt, 15(S)-HETE-sodium salt, 15(R)-HETE-sodium salt and racemic and non-racemic mixtures thereof.
16. The method of Claim 15, wherein the HETE salt is 15(5)-HETE-sodium salt.
17. The method of Claim 14, wherein M" is selected from the group consisting of ] Na*, K* and NH,"
18. The method of Claim 14, wherein the composition comprises an amount of ethanol sufficient to enhance the HETE salt’s efficacy.
19. The method of Claim 14, wherein the amount of ethanol in the composition is
0.001-2% w/v.
20. The method of Claim 19, wherein the amount of ethanol in the composition is
0.005-0.20% w/v.
21. The method of Claim 16, wherein 15(S)-HETE-sodium salt is contained in the composition in a concentration of between 0.00001-0.01% w/v.
22. The method of Claim 21, wherein the composition comprises:
0.00001-0.01% w/v of 15(S)-HETE sodium salt;
0.0505% w/v of ethanol;
0.25% wiv of boric acid;
0.75% wiv of sodium chloride;
0.01% w/v of disodium edetate;
0.001% w/v of polyquaternium-1; and water
23. The method of Claim 22, wherein the composition further comprises polyoxyl 40 stearate in an amount of 0.001 to 2.0% w/v.
24. The method of Claim 14, wherein the composition further comprises one or more artificial tear or phospholipid components.
25. The method of Claim 24, wherein the composition comprises a phospholipid : ] selected from the group consisting of are selected from the group consisting of phosphatidylethanolamines, phosphatidylcholines, phosphatidylserines, ) phospatidylinositols and sphingomyelins.
26. The method of Claim 24, wherein the composition comprises a phospholipid of the formula: 21__ A _-X Ry H—C—X**—R, ) 0 Hef~o—p—, OH Iv)
wherein, X*' and X*? are the same or different and are O, NH(C=0), O(C=0), or a direct bond; R* is H or CH=CH(CH,);,CHs; : xX» R'is OH, or R'is Cl2.26 substituted or unsubstituted alkyl or alkenyl; R? is C|2.26 Substituted or unsubstituted alkyl or alkenyl; and R? is OH, OCH,CH(NH;")COO, OCH,CH,NH;", OCH,CH,N"(CH;),, ) OCH,;CH(OH)CH,0OH and O-inositol.
27. The method of Claim 26, wherein the phospholipid is selected from the group consisting of: DPPC, DPPG, DSPI, SPPC, DPPE, DOPS, DSPE, SPPE, DOPE, DPPS, N-stearyl sphingomyelin, N-palmityl sphingomyelin and N-oleyl sphingomyelin.
28. The method of Claim 24, wherein the composition comprises an artificial tear component selected from the group consisting of monomeric polyols; polymeric polyols; hyaluronic acid; chondroitin sulfate; dextrans; water-soluble proteins; and * vinyl polymers.
29. The method of Claim 28, wherein the artificial tear component is selected from the group consisting of glycerol; propylene glycol; ethylene glycol; polyethylene glycol; hydroxypropylmethyl cellulose; carboxy methylcellulose sodium; hydroxy ’ propylcellulose; hyaluronic acid; chondroitin sulfate; dextran 70; gelatin; polyvinyl alcohol; polyvinylpyrrolidone; povidone; carbomer 934P; carbomer 941; carbomer 940; and carbomer 974P.
30. The method of Claim 14 wherein the dry eye and other disorders requiring wetting of the eye is symptoms of dry eye associated with refractive surgery.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16438299P | 1999-11-09 | 1999-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200202276B true ZA200202276B (en) | 2003-05-28 |
Family
ID=27804646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200202276A ZA200202276B (en) | 1999-11-09 | 2002-03-20 | Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200202276B (en) |
-
2002
- 2002-03-20 ZA ZA200202276A patent/ZA200202276B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6429227B1 (en) | Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders | |
US6353022B1 (en) | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders | |
EP1228026B1 (en) | 15-hydroxyeicosatetraenoic acid-related compounds and methods of use | |
WO2001034129A2 (en) | Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use | |
EP1228027B1 (en) | 3-heteroatom substituted and two carbon homologs of 15-hete and methods of use | |
US6320062B1 (en) | 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders | |
US6255343B1 (en) | 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use | |
US6458853B2 (en) | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use | |
EP1228030B1 (en) | Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders | |
US6458854B2 (en) | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use | |
ZA200202276B (en) | Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders. | |
ZA200202277B (en) | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders. |